| 2026-03-19 | 10-K | 10.23 | Form of Amendment to Stock Option Agreement, dated December 30, 2023, between Eledon Pharmaceuticals, Inc. and David-Alexandre C. Gros, M.D., Steve Perrin, Ph D., Bryan Smith and Paul Little |
|---|
| 2026-03-19 | 10-K | 10.22 | Form of Stock Option Agreement, dated May 1, 2023, between Eledon Pharmaceuticals, Inc. and each of David-Alexandre C. Gros, M.D., Steve Perrin, Ph D., Bryan Smith and Paul Little |
|---|
| 2025-03-20 | 10-K | 10.26 | Form of Amendment to Stock Option Agreement, dated November 20, 2024, between Eledon Pharmaceuticals, Inc. and David-Alexandre C. Gros, M.D., Steve Perrin, Ph D., Bryan Smith and Paul Little |
|---|
| 2025-03-20 | 10-K | 10.25 | Form of Amendment to Stock Option Agreement, dated June 13, 2024, between Eledon Pharmaceuticals, Inc. and David-Alexandre C. Gros, M.D., Steve Perrin, Ph D., Bryan Smith and Paul Little |
|---|
| 2025-03-20 | 10-K | 10.14 | David-Alexandre Gros, M.D. Letter Agreement, dated December 16, 2024 |
|---|
| 2025-03-20 | 10-K | 10.8 | Lease Agreement, dated September 4, 2024, by and between Blanchard Group LLC and Eledon Pharmaceuticals, Inc. |
|---|
| 2025-03-20 | 10-K | 10.7 | Fourth Amendment to Lease Agreement, dated March 12, 2024, by and between Newport Gateway Office LLC and Eledon Pharmaceuticals, Inc. |
|---|
| 2024-07-10 | 8-K | 10.1 | Eledon Pharmaceuticals, Inc. 2020 Long Term Incentive Plan, as amended |
|---|
| 2024-05-07 | 8-K | 10.2 | Registration Rights Agreement, dated May 6, 2024 |
|---|
| 2024-05-07 | 8-K | 10.1 | Securities Purchase Agreement, dated May 6, 2024 |
|---|
| 2024-03-28 | 10-K | 10.23 | Form of Amendment to Stock Option Agreement, dated December 30, 2023, between Eledon Pharmaceuticals, Inc. and David-Alexandre C. Gros, M.D., Steve Perrin, Ph D. and Paul Little |
|---|
| 2024-03-28 | 10-K | 10.22 | Form of Stock Option Agreement, dated May 1, 2023, between Eledon Pharmaceuticals, Inc. and each of David-Alexandre C. Gros, M.D., Steve Perrin, Ph D. and Paul Little |
|---|
| 2023-09-21 | 8-K | 10.1 | Form of Indemnification Agreement to be entered into with each of the directors and officers of Eledon |
|---|
| 2023-06-22 | 8-K | 10.1 | Eledon Pharmaceuticals, Inc. 2020 Long Term Incentive Plan, as amended |
|---|
| 2023-05-01 | 8-K | 10.4 | Steven Perrin, Ph.D. Letter Agreement, dated April 27, 2023 |
|---|
| 2023-05-01 | 8-K | 10.3 | David-Alexandre Gros, M.D. Letter Agreement, dated April 27, 2023 |
|---|
| 2023-05-01 | 8-K | 10.2 | Registration Rights Agreement, dated April 28, 2023 |
|---|
| 2023-05-01 | 8-K | 10.1 | Securities Purchase Agreement, dated April 28, 2023 |
|---|
| 2022-08-11 | 10-Q | 10.3 | License Agreement between Lonza Sales AG and Anelixis Therapeutics, LLC, dated September 11, 2018 |
|---|
| 2022-08-11 | 10-Q | 10.2 | First Amendment to Restated License Agreement between ALS Therapy Development Foundation, Inc. and Anelixis Therapeutics, Inc. dated September 5, 2020 |
|---|
| 2022-08-11 | 10-Q | 10.1 | Amended and Restated License Agreement by and between ALS Therapy Development Foundation, Inc. and Anelixis Therapeutics, Inc, dated February 18, 2020 |
|---|
| 2022-03-24 | 10-K | 10.14 | Sublease Agreement, dated as of November 4, 2021, by and between Corporate Technologies, Inc. and Eledon Pharmaceuticals, Inc. |
|---|
| 2022-03-24 | 10-K | 10.13 | Second Amendment to Lease Agreement, dated May 3, 2021, by and between Newport Gateway Office LLC and Eledon Pharmaceuticals, Inc. |
|---|
| 2022-03-24 | 10-K | 10.12 | Performance Stock Option Agreement, dated February 1, 2022, between Eledon Pharmaceuticals, Inc. and David-Alexandre C. Gros, M.D. |
|---|
| 2022-01-13 | 8-K | 10.1 | Series X1 Exchange Agreement, dated January 11, 2022, by and among Eledon Pharmaceuticals, Inc. and the Stockholders named therein |
|---|
| 2021-03-31 | 10-K | 10.11 | Novus Therapeutics, Inc., 2020 Long Term Incentive Plan |
|---|
| 2021-03-31 | 10-K | 10.10 | Executive Employment Agreement, dated March 15, 2021, between Eledon Pharmaceuticals, Inc. and Paul Little |
|---|
| 2021-03-31 | 10-K | 10.9 | Executive Employment Agreement, dated March 1, 2021, between Eledon Pharmaceuticals, Inc. and Jon Kuwahara |
|---|
| 2021-03-31 | 10-K | 10.8 | Executive Employment Agreement, dated September 9, 2020, between Novus Therapeutics, Inc. and David-Alexandre C. Gros, M.D. |
|---|
| 2021-01-07 | 8-K | 10.2 | Warrant Exchange Agreement, dated December 31, 2020, by and among Novus Therapeutics, Inc. and the Stockholders named therein |
|---|
| 2021-01-07 | 8-K | 10.1 | Series X Exchange Agreement, dated December 31, 2020, by and among Novus Therapeutics, Inc. and the Stockholders named therein |
|---|
| 2020-09-15 | 8-K | 10.2 | Form of Registration Rights Agreement, by and among Novus Therapeutics, Inc. and certain purchasers |
|---|
| 2020-09-15 | 8-K | 10.1 | Stock Purchase Agreement, dated as of September 14, 2020, by and among Novus Therapeutics, Inc. and each purchaser identified on Annex A thereto |
|---|
| 2020-02-19 | 8-K | 10.1 | Exchange Agreement, dated February 13, 2020, by and among Novus Therapeutics, Inc. and the Stockholders named therein |
|---|
| 2020-01-16 | 8-K | 10.1 | Form of Warrant Exercise Agreement by and between Novus Therapeutics, Inc. and the Holders named therein |
|---|
| 2019-05-14 | 10-Q | 10.1 | Management Continuity Agreement, date August 7, 2017, between Novus Therapeutics, Inc. and Catherine C. Turkel |
|---|
| 2019-05-02 | 8-K | 10.1 | Form of Securities Purchase Agreement, dated April 30, 2019, by and between Novus Therapeutics, Inc. and the Purchasers named therein |
|---|
| 2019-03-28 | 10-K | 10.15 | Executive Employment Agreement, dated November 10, 2015, between Otic Pharma, Inc. and Catherine C. Turkel |
|---|
| 2018-08-07 | 10-Q | 10.3 | Novus Therapeutics, Inc., 2014 Employee Stock Purchase Plan |
|---|
| 2018-08-07 | 10-Q | 10.2 | Novus Therapeutics, Inc., 2014 Stock Incentive Plan |
|---|
| 2018-08-07 | 10-Q | 10.1 | First Amendment to Lease Agreement, dated April 9, 2018, by and between The Irvine Company LLC and Novus Therapeutics, Inc. |
|---|
| 2018-04-02 | 10-K | 10.12 | Tokai Pharmaceuticals, Inc. 2014 Stock Incentive Plan |
|---|
| 2018-04-02 | 10-K | 10.11 | Tokai Pharmaceuticals, Inc. 2007 Stock Incentive Plan |
|---|
| 2018-04-02 | 10-K | 10.10 | Otic Pharma Ltd. Global Share Incentive Plan (2012) |
|---|
| 2017-08-09 | 10-Q | 10.7 | Management Continuity Agreement, dated August 7, 2017, between Novus Therapeutics, Inc. and Jon S. Kuwahara. |
|---|
| 2017-08-09 | 10-Q | 10.6 | Management Continuity Agreement, dated August 7, 2017, between Novus Therapeutics, Inc. and Gregory J. Flesher. |
|---|
| 2017-08-09 | 10-Q | 10.5 | Offer of Employment, dated July 1, 2017, from Novus Therapeutics, Inc. to Jon Kuwahara. |
|---|
| 2017-08-09 | 10-Q | 10.4 | Exclusive License Agreement, dated November 1, 2015, between Scientific Development and Research, Inc. and Otodyne, Inc., on the one hand, and Oticpharma, Inc., on the other hand. |
|---|
| 2017-08-09 | 10-Q | 10.3 | Executive Employment Agreement, dated July 15, 2015, between Otic Pharma, Inc., and Gregory J. Flesher. |
|---|
| 2017-08-09 | 10-Q | 10.2 | Lease Agreement, dated as of September 2, 2015, by and between The Irvine Company LLC and Otic Pharma, Inc. |
|---|
| 2017-08-09 | 10-Q | 10.1 | Form of Indemnification Agreement between Novus Therapeutics, Inc. and each of its directors and executive officers. |
|---|
| 2017-05-15 | 8-K | 10.1 | Registration Rights Agreement, dated May 10, 2017, by and among the Company and the Purchasers. |
|---|
| 2017-02-03 | 8-K | 10.1 | Stock Purchase Agreement, dated as of January 31, 2017, by and among Tokai and the Purchasers named therein. |
|---|
| 2016-12-22 | 8-K | 10.2 | Commitment Letter dated as of December 21, 2016 entered into by and among Tokai, Otic and certain purchasers named therein. |
|---|
| 2016-12-22 | 8-K | 10.1 | Support Agreement dated as of December 21, 2016 entered into by and among Tokai, Otic and certain stockholders of Tokai. |
|---|
| 2016-11-03 | 10-Q | 10.3 | Consulting Agreement dated September 21, 2016 between the Registrant and Apple Tree Life Sciences, Inc. |
|---|
| 2016-11-03 | 10-Q | 10.2 | Consulting Agreement dated August 31, 2016 between the Registrant and Karen J. Ferrante |
|---|
| 2016-11-03 | 10-Q | 10.1 | Consulting Agreement dated August 31, 2016 between the Registrant and Lee H. Kalowski |
|---|
| 2016-05-10 | 10-Q | 10.1 | Fourth Amendment to Master License Agreement between the Registrant and the University of Maryland, Baltimore, dated as of March 15, 2016. |
|---|
| 2015-08-12 | 10-Q | 10.2 | Employment Letter, dated as of April 7, 2015, between the Registrant and Gerald E. Quirk. Filed herewith. |
|---|
| 2015-08-12 | 10-Q | 10.1 | Lease, executed on June 9, 2015, between the Registrant and 255 State Street LLC. Filed herewith. |
|---|
| 2015-05-12 | 10-Q | 10.1 | Master Collaboration Agreement, dated January 12, 2015, between the Registrant and Qiagen Manchester Limited |
|---|
| 2015-03-26 | 10-K | 10.20 | License Agreement, dated as of January 9, 2015, between the Registrant and The Johns Hopkins University |
|---|
| 2015-03-26 | 10-K | 10.18 | Sublease Agreement, dated as of February 27, 2015, between the Registrant and Boston Private Wealth LLC |
|---|
| 2015-03-26 | 10-K | 10.16 | Amendment to Employment Letter, dated as of January 15, 2015, between the Registrant and Lee H. Kalowski |
|---|
| 2015-03-26 | 10-K | 10.14 | Amendment to Employment Letter, dated as of January 15, 2015, between the Registrant and Karen J. Ferrante |
|---|
| 2015-03-26 | 10-K | 10.12 | Amendment to Employment Letter, dated as of January 15, 2015, between the Registrant and John S. McBride |
|---|
| 2015-03-26 | 10-K | 10.10 | Amendment to Employment Letter, dated as of January 15, 2015, between the Registrant and Jodie P. Morrison |
|---|